Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 16/20 | 1.00 |
| ▸ | F2 | P00734 | 6/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 5/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 5/20 | 1.00 |
| ▸ | KLK1 | P06870 | 4/20 | 1.00 |
| ▸ | HGFAC | Q04756 | 3/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | HPN | P05981 | 1/20 | 1.00 |
| ▸ | CTSL | P07711 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | ACR | P10323 | 10/20 | 0.61 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camostat SCHEMBL29376746 | 0.95 | PRSS1 (1.00) | PRSS1F2PRSS2PRSS3KLK1 | |
| SCHEMBL21920058 | 0.85 | PRSS1 (0.74) | PRSS1F2PRSS2PRSS3KLK1 | |
| SCHEMBL13283061 | 0.81 | PRSS1 (0.68) | PRSS1F2PRSS2PRSS3KLK1 | |
| Camostat SCHEMBL125269 | 0.81 | PRSS1 (0.68) | PRSS1F2PRSS2PRSS3KLK1 | |
| SCHEMBL20008640 | 0.81 | PRSS1 (0.68) | PRSS1F2PRSS2PRSS3KLK1 | |
| Camostat SCHEMBL2782237 | 0.80 | PRSS1 (0.67) | PRSS1F2PRSS2PRSS3KLK1 | |
| Camostat SCHEMBL8829828 | 0.79 | PRSS1 (0.66) | PRSS1F2PRSS2PRSS3KLK1 | |
| SCHEMBL4752946 | 0.79 | PRSS1 (0.66) | PRSS1F2PRSS2PRSS3KLK1 | |
| Camostat SCHEMBL1645380 | 0.79 | PRSS1 (0.64) | PRSS1F2PRSS2PRSS3KLK1 | |
| Camostat SCHEMBL1645520 | 0.78 | PRSS1 (0.63) | PRSS1F2PRSS2PRSS3KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3784 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260139035-A1 | HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2026-05-21 | — | — | US | claimed |
| US-20260130921-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem Incorporated (US) | 2026-05-14 | — | — | US | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-12527762-B2 | Cocrystal comprising camostat and niclosamide, pharmaceutical composition comprising same and preparation method therefor | IMDPHARM INC. (KR) | 2026-01-20 | — | — | US | claimed |
| US-20260007597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2026-01-08 | — | — | US | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2006048777-A2 | MODIFIED GROWTH HORMONES | NAUTILUS BIOTECH (US) | 2006-05-11 | — | — | WO | claimed |
| US-20040223958-A1 | Glutathione reductase for therapy and prophylaxis of AIDS | ANSOVINI RAFFAELE (IT) | 2004-11-11 | — | — | US | claimed |
| EP-1178819-B1 | GLUTATHIONE REDUCTASE FOR THERAPY AND PROPHYLAXIS OF AIDS | ANSOVINI RAFFAELE (IT) | 2003-11-12 | — | — | EP | claimed |
| EP-1178819-A2 | GLUTATHIONE REDUCTASE FOR THERAPY AND PROPHYLAXIS OF AIDS | Ansovini, Raffaele (IT) | 2002-02-13 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000071146-A2 | GLUTATHIONE REDUCTASE FOR THERAPY AND PROPHYLAXIS OF AIDS | ANSOVINI RAFFAELE (IT) | 2000-11-30 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5468727-A | Methods of normalizing metabolic parameters in diabetics | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 1995-11-21 | — | — | US | claimed |